Reviewed and published CART studies in hematologic malignancies
| Target antigen (diseases treated) . | No. of studies . | No. of patients . | Results . | Notes . |
|---|---|---|---|---|
| CD19 | ||||
| (ALL) | 9 | 264 | 30%-90% CR | Mixture of vectors and costimulatory domains, some CD19− relapses, many went on to subsequent HSCT where there were no CD19− relapses |
| (CLL) | 7 | 31 | 20%-75% CR, 15%-30% PR | Lymphodepletion improved outcomes |
| (NHL) | 13 | 151 | 40%-100% CR | Mixture of histologies, vectors, and costimulatory domains, no GVHD seen, lymphodepletion improved outcomes |
| (MM) | 1 | 1 | Stringent CR | CART given after auto-HSCT |
| CD20 (NHL) | 1 | 4 | 1 PR, 2 remained in remission | Used in consolidation or for residual disease |
| CD22 (NHL) | 1 | 6 | 1 CR, 2 SD | Most with CD19− relapse |
| CD30 (HOD) | 2 | 27 | 1 CR, 8 PR, 10 SD, 8 PD | |
| CD33 (AML) | 1 | 1 | Transient reduction in blasts | |
| CD123 (AML) | 1 | 1 | Transient reduction in blasts | |
| BCMA (MM) | 1 | 11 | 1 VGPR, 2 SD, 1 CR | Improved response with higher-dose cohort |
| LeY (AML) | 1 | 4 | 1 transient CR, 1 transient reduction in blasts, 2 SD | CART could be detected in sites of extramedullary disease |
| Target antigen (diseases treated) . | No. of studies . | No. of patients . | Results . | Notes . |
|---|---|---|---|---|
| CD19 | ||||
| (ALL) | 9 | 264 | 30%-90% CR | Mixture of vectors and costimulatory domains, some CD19− relapses, many went on to subsequent HSCT where there were no CD19− relapses |
| (CLL) | 7 | 31 | 20%-75% CR, 15%-30% PR | Lymphodepletion improved outcomes |
| (NHL) | 13 | 151 | 40%-100% CR | Mixture of histologies, vectors, and costimulatory domains, no GVHD seen, lymphodepletion improved outcomes |
| (MM) | 1 | 1 | Stringent CR | CART given after auto-HSCT |
| CD20 (NHL) | 1 | 4 | 1 PR, 2 remained in remission | Used in consolidation or for residual disease |
| CD22 (NHL) | 1 | 6 | 1 CR, 2 SD | Most with CD19− relapse |
| CD30 (HOD) | 2 | 27 | 1 CR, 8 PR, 10 SD, 8 PD | |
| CD33 (AML) | 1 | 1 | Transient reduction in blasts | |
| CD123 (AML) | 1 | 1 | Transient reduction in blasts | |
| BCMA (MM) | 1 | 11 | 1 VGPR, 2 SD, 1 CR | Improved response with higher-dose cohort |
| LeY (AML) | 1 | 4 | 1 transient CR, 1 transient reduction in blasts, 2 SD | CART could be detected in sites of extramedullary disease |
Data from Kenderian et al1 and supplemented with PubMed search (May 2017).
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BCMA, B-cell maturation antigen; CART, chimeric antigen receptor T cell; CLL, chryonic lymphocytic leukemia; CR, complete response; GVHD, graft-versus-host disease; HOD, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very-good partial remission.